221 related articles for article (PubMed ID: 17032501)
1. Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.
Lee OJ; Hong SM; Razvi MH; Peng D; Powell SM; Smoklin M; Moskaluk CA; El-Rifai W
Neoplasia; 2006 Oct; 8(10):843-50. PubMed ID: 17032501
[TBL] [Abstract][Full Text] [Related]
2. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes.
Matsubara D; Niki T; Ishikawa S; Goto A; Ohara E; Yokomizo T; Heizmann CW; Aburatani H; Moriyama S; Moriyama H; Nishimura Y; Funata N; Fukayama M
Cancer Sci; 2005 Dec; 96(12):844-57. PubMed ID: 16367903
[TBL] [Abstract][Full Text] [Related]
4. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
[TBL] [Abstract][Full Text] [Related]
5. High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
Wang YY; Ye ZY; Zhao ZS; Tao HQ; Chu YQ
Ann Surg Oncol; 2010 Jan; 17(1):89-97. PubMed ID: 19820999
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of altered S100A2 expression in gastric cancer.
Zhao Y; Zhang TB; Wang Q
Oncol Rep; 2013 Apr; 29(4):1556-62. PubMed ID: 23337980
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
8. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W
Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808
[TBL] [Abstract][Full Text] [Related]
10. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
12. S100 calcium-binding protein A4 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.
Zhao Y; Zhang T; Wang Q
Oncol Rep; 2013 Jul; 30(1):111-8. PubMed ID: 23612849
[TBL] [Abstract][Full Text] [Related]
13. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
14. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.
Luo J; Zhu Y; Yang G; Gong L; Wang B; Liu H
Diagn Cytopathol; 2011 Oct; 39(10):752-7. PubMed ID: 20949468
[TBL] [Abstract][Full Text] [Related]
15. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
16. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
von Rahden BH; Stein HJ; Feith M; PĂĽhringer F; Theisen J; Siewert JR; Sarbia M
Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
[TBL] [Abstract][Full Text] [Related]
18. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.
Marketkar S; Li D; Yang D; Cao W
World J Gastroenterol; 2017 Feb; 23(8):1338-1344. PubMed ID: 28293080
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.
Gupta S; Hussain T; MacLennan GT; Fu P; Patel J; Mukhtar H
J Clin Oncol; 2003 Jan; 21(1):106-12. PubMed ID: 12506178
[TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]